Our top pick for
Cleveland BioLabs, Inc is a biotechnology business based in the US. Cleveland BioLabs shares (CBLI) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 2 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$1.43 - $9.53|
|50-day moving average||$5.74|
|200-day moving average||$4.45|
|Wall St. target price||$2.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$-428,128|
|Return on assets TTM||-74.24%|
|Return on equity TTM||-162.65%|
|Market capitalisation||$85.1 million|
TTM: trailing 12 months
There are currently 108,660 Cleveland BioLabs shares held short by investors – that's known as Cleveland BioLabs's "short interest". This figure is 99% up from 54,593 last month.
There are a few different ways that this level of interest in shorting Cleveland BioLabs shares can be evaluated.
Cleveland BioLabs's "short interest ratio" (SIR) is the quantity of Cleveland BioLabs shares currently shorted divided by the average quantity of Cleveland BioLabs shares traded daily (recently around 205018.86792453). Cleveland BioLabs's SIR currently stands at 0.53. In other words for every 100,000 Cleveland BioLabs shares traded daily on the market, roughly 530 shares are currently held short.
However Cleveland BioLabs's short interest can also be evaluated against the total number of Cleveland BioLabs shares, or, against the total number of tradable Cleveland BioLabs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cleveland BioLabs's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cleveland BioLabs shares in existence, roughly 10 shares are currently held short) or 0.0122% of the tradable shares (for every 100,000 tradable Cleveland BioLabs shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cleveland BioLabs.
Find out more about how you can short Cleveland BioLabs stock.
We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.
Cleveland BioLabs's shares were split on a 1:20 basis on 27 January 2015. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.
Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $1.43 up to $9.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.7038. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).
Cleveland BioLabs, Inc. , a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and immuno-oncology. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand; and CBL0137, a small molecule with a multi-targeted mechanism for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, Rusnano, and Everon Biosciences.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.